A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy

StatusActive, Not Recruiting
PhasePhase 3
Started

Record status This record was last updated August 24, 2026 (before its estimated September 2026 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment closed, study ongoing
    • Enrollment target: estimated 216 to confirmed 228
    • Site details revised
    v3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Aug 2025 to Aug 11, 2025
    • Site details revised
    v2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study is being conducted to evaluate the efficacy and safety of HRS-1893 for obstructive hypertrophic cardiomyopathy.
Trial Details
NCT Number NCT07021976
Lead Sponsor Shandong Suncadia Medicine Co., Ltd.
Conditions
(from sponsor)		 Obstructive Hypertrophic Cardiomyopathy
Related terms Cardiomyopathy, Hypertrophic
Enrollment 228 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov